Diagnostic Imaging Market Partnering Terms and Agreements - a New Research Report Available at ReportsnReports.com
Dallas, Texas (PRWEB) August 06, 2014 -- The Diagnostic Imaging Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering agreements entered into by the worlds leading healthcare companies.
The “Diagnostic Imaging Partnering Terms and Agreements” report provides a detailed understanding and analysis of how and why companies enter diagnostic imaging partnering deals. This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:
• Imaging
• CT
• Endoscope
• Molecular and nuclear
• PET
• SPECT
• MRI
• Ultrasound
• X ray
• Angiography
• Fluoroscopy
• Mammography
This report provides an overview of diagnostic imaging dealmaking, the common clauses, rights and options in the partnering agreement, and also a comprehensive review of deals signed in since 2009.
Purchase Report @ http://www.reportsnreports.com/purchase.aspx?name=293408.
This report provides a comprehensive and detailed review of all diagnostic imaging deals announced since 2009. The comprehensive agreements chapter is organized by company A-Z, stage of development at signing, deal type, and therapy focus. Each deal title links via Weblink to an online version of the actual deal at Current Agreements deals and alliances database, providing easy access to each deal on demand. Where available, the full deal contract document is also provided and indicated by a document symbol.
Contract documents provide unsurpassed access to the detail of a deal normally announced in brief summary through a press release. Detailed analysis of a contract allow better understanding of the terms agreed between the parties, and importantly the basis under which monies and licensing rights are exchanged.
For example, analyzing actual company agreements allows assessment of the following:
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What are the precise rights granted or optioned?
• What is the payment structure for the deal?
• How aresalesand payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?
Diagnostic Imaging Partnering Terms and Agreements includes:
• Trends in diagnostic imaging dealmaking in the biopharma industry since 2009
• Analysis of diagnostic imaging deal structure
• Access to headline, upfront, milestone and royalty data
• Case studies of real-life diagnostic imaging deals
• Access to over 700 diagnostic imaging deal documents
• The leading vaccine deals by value since 2009
• Most active diagnostic imaging dealmakers since 2009
• The leading diagnostic imaging partnering resources
In Diagnostic Imaging Partnering Terms and Agreements, the available contracts are listed by:
• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Therapy target
• Specific technology type
The Diagnostic Imaging Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 700 diagnostic imaging deals. Analyzing actual contract agreements allows assessment of the following:
• What are the precise vaccine rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?
Other New Reports:
Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics.
Co-Development Terms and Agreements in Pharma, Biotech and Diagnostics.
These reports contain links to online copies of actual collaborative R&D contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
About US
ReportsnReports.com is an online market research reports library of 200,000+ reports and in-depth studies of 5000+ micro markets. Call +1 888 391 5441 with your industry research requirements or email the details on sales at reportsandreports.com.
Ritesh Tiwari, ReportsnReports.com, http://www.reportsnreports.com/, +1 (888) 391-5441, [email protected]
Share this article